PARP1 and neoplasm: The investigational PARP-1 and PARP-2 inhibitor Pamiparib has also shown promising antitumor efficacy, suppressing the proliferation of tumor cell lines harboring BRCA1/2 mutations or HRD (Wang et al., 2020).